Colorado Retina Associates offers a robust, in-house clinical research program to all of our patients. We participate in some of the most innovative research and clinical trials surrounding retina treatments, diagnosis, and cures for blindness. At Colorado Retina, we believe that ongoing research into disease states and treatments is a vital part of improving our patients’ well-being. We are committed to participating in cutting-edge research, allowing our patients to have access to the latest treatments and drug options, while furthering scientific developments and changing the future of retina.
Clinical trials are essential in advancing medical knowledge and result in developing new ways to prevent, detect, or treat disease.
Trials can also confirm if established treatments are equal to or better than new ones. At Colorado Retina we have been involved with hundreds of clinical research trials that have significantly advanced our understanding of eye disease and have made numerous new treatments available to our patients.
Our goal is to ultimately improve the health and quality of life of our patients, and research is one of the many ways we seek to achieve that.
Access to new treatments and drugs before they are released to the market
Help advance new treatments
Extra care, attention, and follow up provided by our trained and dedicated research professionals
Improvement in physical well-being and quality of life
Stipends, driving allowances, and other incentives
Before you consent to join a clinical trial, it is important for you to have all the information you need to be confident about your decision. When you choose to take part in a clinical trial, you may or may not improve your health. You may also be one of the first to try a promising new drug or treatment. Be sure you have answers to all your questions, and full knowledge of what is involved. Then, weigh your options and discuss with your family or support system.
For more information or questions regarding clinical trials, email the Colorado Retina research department.
Frank Garcia, Director of Clinical Research at Colorado Retina, has been active in the medical field of clinical research for 12 years. Frank focuses on facilitating high quality ophthalmic clinical trials, innovative recruitment initiatives and continuing the development of CRA’s talented research team.
Before starting in clinical research, Frank spent six years as an Organ Procurement Coordinator and Surgical Specialist. After a successful career helping standardize procurement procedures in the venue of kidney pump optimization, Frank now uses his clinical experience to build robust process in the operationalizing of clinical research trials.
Outside clinic, Frank enjoys trying new food and wine, as well as spending time with his loved ones.
For more information about Colorado Retina’s clinical research department, actively enrolling or upcoming studies, contact Frank Garcia by calling the research department at (720) 420-3265 or by email at fgarcia@retinacolorado.com.
The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD).
Vital dyes are an essential tool of retina surgeons who perform macular surgery, specifically peeling of epiretinal membranes or the internal limiting membrane.
Although no major studies have analyzed this phenomenon, anecdotal evidence can be instructive.
